DIA Daily | AstraZeneca, Roche Replacing "Aging Blockbusters"
AstraZeneca, Roche Replacing “Aging Blockbusters” With New Drugs.
Bloomberg News
Bloomberg News(7/26, Lauerman, Kresge) reports AstraZeneca and Roche are replacing sales of “aging blockbusters” facing generic competition with “new drugs for cancer, heart disease and multiple sclerosis” that are “taking over as the engines of growth.” Astra is replacing sales lost due to generic competition of its heart drug Crestor (Rosuvastatin) and Symbicort (budesonide/formoterol) for asthma with “cuts and new products including Lynparza (olaparib) for breast cancer and Imfinzi (Durvalumab) for lung cancer.” Similarly, Roche’s breast cancer drug Herceptin (trastuzumab) “faced its first competition from biosimilars in Europe, causing sales to drop 7 percent there last quarter.” But the company’s new MS drug Ocrevus (ocrelizumab) and next-generation breast cancer medicine Perjeta (pertuzumab) saw sales go up significantly last quarter.
相关连接：
http://mailview.bulletinhealthcare.com/mailview.aspx?m=2018072701dia&r=7819783-50fd&l=007-9fc&t=c
Fierce Pharma
Fierce Pharma(7/26, Liu) reports Roche CEO Severin Schwan called Ocrevus “the most successful launch in the history of Roche” on the company’s first-half earnings call Thursday. Ocrevus was “so successful that it crossed the blockbuster threshold halfway through 2018, after being on the market for just over a year.” In the first six months of 2018, it brought in $1.05 billion, more than 90 percent of that in the US.
相关连接：
http://mailview.bulletinhealthcare.com/mailview.aspx?m=2018072701dia&r=7819783-50fd&l=008-a66&t=c
DIA会员
▲点击图片了解详情
DIA NOW
▲点击图片了解详情
推荐阅读
关于DIA
DIA总部位于美国首都Washington DC，此外在北美、欧洲、日本、中国等设有分部。作为一家中立的国际组织，DIA 在制药和其它医疗健康领域，孜孜不倦50余年，为政府，工业和学术机构提供了形式多样的交流和学习的平台，赢得广泛认可和赞誉。
DIA是中国医药健康研发领域必不可缺的专业分享和知识更新的伙伴
DIA微信订阅号
全新上线 ！
DIA微信
订阅号
◀ 关注我
长按识别左侧二维码即可关注
我们努力为你提供有内容的内容。